Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Anaplastic lymphoma kinase (ALK) rearrangements are present in about 5–6% of non-small cell lung cancer (NSCLC) cases and associated with increased risks of central nervous system (CNS) involvement. Envonalkib, a novel ALK inhibitor, demonstrated promising anti-tumor activity and safety in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yunpeng, Min, Jie, Yang, Nong, Yu, Qitao, Cheng, Ying, Zhao, Yanqiu, Li, Manxiang, Chen, Hong, Ren, Shou’an, Zhou, Jianying, Zhuang, Wu, Qin, Xintian, Cao, Lejie, Yu, Yan, Zhang, Jian, He, Jianxing, Feng, Jifeng, Yu, Hao, Zhang, Li, Fang, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423717/
https://www.ncbi.nlm.nih.gov/pubmed/37574511
http://dx.doi.org/10.1038/s41392-023-01538-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423717/
https://www.ncbi.nlm.nih.gov/pubmed/37574511
http://dx.doi.org/10.1038/s41392-023-01538-w

Ejemplares similares